{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:36:51Z","timestamp":1788716211368,"version":"build-2803163510"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00705-019-04479-4","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T13:02:33Z","timestamp":1575464553000},"page":"263-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review"],"prefix":"10.1007","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-370X","authenticated-orcid":false,"given":"Tahoora","family":"Mousavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sogol","family":"Sattari Saravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Valadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Haghshenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Rafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Jafarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shamshirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"issue":"4","key":"4479_CR1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","volume":"55","author":"F Bosch","year":"2002","unstructured":"Bosch F, Lorincz A, Munoz N, Meijer C, Shah K (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244\u2013265","journal-title":"J Clin Pathol"},{"issue":"5","key":"4479_CR2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386","journal-title":"Int J Cancer"},{"key":"4479_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/2008-7802.201658","volume":"8","author":"MR Haghshenas","year":"2017","unstructured":"Haghshenas MR, Mousavi T, Kheradmand M, Afshari M, Moosazadeh M (2017) Efficacy of human papillomavirus l1 protein vaccines (cervarix and gardasil) in reducing the risk of cervical intraepithelial neoplasia: a meta-analysis. Int J Prev Med 8:14","journal-title":"Int J Prev Med"},{"issue":"53","key":"4479_CR4","first-page":"275","volume":"3","author":"AGU Amarakoon","year":"2016","unstructured":"Amarakoon AGU, Daulagala S, Fathima F (2016) An overview of human papilloma virus. World Sci News 3(53):275\u2013308","journal-title":"World Sci News"},{"issue":"1","key":"4479_CR5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","volume":"23","author":"A Yang","year":"2016","unstructured":"Yang A, Farmer E, Wu T, Hung C-F (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23(1):75","journal-title":"J Biomed Sci"},{"issue":"3","key":"4479_CR6","first-page":"231","volume":"19","author":"MR Haghshenas","year":"2016","unstructured":"Haghshenas MR, Mousavi T, Moosazadeh M, Afshari M (2016) Human papillomavirus and breast cancer in Iran: a meta-analysis. Iran J Basic Med Sci 19(3):231","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"4479_CR7","first-page":"159","volume":"4","author":"F Niazy","year":"2015","unstructured":"Niazy F, Rostami K, Motabar AR (2015) Giant condyloma acuminatum of vulva frustrating treatment challenge. World J Plast Surg 4(2):159","journal-title":"World J Plast Surg"},{"issue":"4","key":"4479_CR8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ijc.31094","volume":"142","author":"R Landy","year":"2018","unstructured":"Landy R, Windridge P, Gillman MS, Sasieni PD (2018) What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer 142(4):709\u2013718","journal-title":"Int J Cancer"},{"issue":"4","key":"4479_CR9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1155\/2007\/136906","volume":"23","author":"A-B Moscicki","year":"2007","unstructured":"Moscicki A-B (2007) HPV infections in adolescents. Dis Mark 23(4):229\u2013234","journal-title":"Dis Mark"},{"issue":"1","key":"4479_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00404-013-2938-1","volume":"289","author":"HL Wang","year":"2014","unstructured":"Wang HL, Xu H, Lu WH, Zhu L, Yu YH, Hong FZ (2014) In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer. Arch Gynecol Obstet 289(1):155\u2013162","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"4479_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1447-0756.2009.01167.x","volume":"36","author":"N Bhatla","year":"2010","unstructured":"Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D et al (2010) Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 36(1):123\u2013132","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"4479_CR12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1155\/2007\/914823","volume":"23","author":"FX Bosch","year":"2007","unstructured":"Bosch FX, de Sanjos\u00e9 S (2007) The epidemiology of human papillomavirus infection and cervical cancer. Dis Mark 23(4):213\u2013227","journal-title":"Dis Mark"},{"issue":"12","key":"4479_CR13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s00262-005-0685-2","volume":"54","author":"Z Cui","year":"2005","unstructured":"Cui Z, Huang L (2005) Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 54(12):1180\u20131190","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4479_CR14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1071\/SH09132","volume":"7","author":"IH Frazer","year":"2010","unstructured":"Frazer IH (2010) Cervical cancer vaccine development. Sex Health 7(3):230\u2013234","journal-title":"Sex Health"},{"issue":"329","key":"4479_CR15","first-page":"85","volume":"100","author":"RK Gherardi","year":"2016","unstructured":"Gherardi RK, Aouizerate J, Cadusseau J, Yara S, Authier FJ (2016) Aluminum adjuvants of vaccines injected into the muscle: normal fate, pathology and associated disease. Morphologie bulletin de l\u2019Association des anatomistes 100(329):85\u201394","journal-title":"Morphologie bulletin de l\u2019Association des anatomistes"},{"issue":"8","key":"4479_CR16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"5","key":"4479_CR17","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1101004","volume":"187","author":"SC de Cassan","year":"2011","unstructured":"de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P et al (2011) The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol (Baltimore, Md: 1950) 187(5):2602\u20132616","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"3","key":"4479_CR18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1179\/136485910X12647085215534","volume":"104","author":"AL Goodman","year":"2010","unstructured":"Goodman AL, Draper SJ (2010) Blood-stage malaria vaccines\u2014recent progress and future challenges. Ann Trop Med Parasitol 104(3):189\u2013211","journal-title":"Ann Trop Med Parasitol"},{"issue":"13","key":"4479_CR19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/0961203309345724","volume":"18","author":"E Israeli","year":"2009","unstructured":"Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18(13):1217\u20131225","journal-title":"Lupus"},{"issue":"Suppl 2","key":"4479_CR20","doi-asserted-by":"crossref","first-page":"B44","DOI":"10.1016\/j.vaccine.2015.02.073","volume":"33","author":"BG Gellin","year":"2015","unstructured":"Gellin BG, Salisbury DM (2015) Communicating the role and value of vaccine adjuvants. Vaccine 33(Suppl 2):B44\u2013B46","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"4479_CR21","doi-asserted-by":"crossref","first-page":"B40","DOI":"10.1016\/j.vaccine.2015.03.057","volume":"33","author":"R Seder","year":"2015","unstructured":"Seder R, Reed SG, O\u2019Hagan D, Malyala P, D\u2019Oro U, Laera D et al (2015) Gaps in knowledge and prospects for research of adjuvanted vaccines. Vaccine 33(Suppl 2):B40\u2013B43","journal-title":"Vaccine"},{"issue":"7","key":"4479_CR22","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.28840","volume":"10","author":"S Kashiwagi","year":"2014","unstructured":"Kashiwagi S, Brauns T, Gelfand J, Poznansky MC (2014) Laser vaccine adjuvants. History, progress, and potential. Hum Vaccines Immunother 10(7):1892\u20131907","journal-title":"Hum Vaccines Immunother"},{"issue":"10","key":"4479_CR23","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, Von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 4(10):e297","journal-title":"PLoS Med"},{"issue":"11","key":"4479_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/cns.12469","volume":"21","author":"Y Li","year":"2015","unstructured":"Li Y, Xu XL, Zhao D, Pan LN, Huang CW, Guo LJ et al (2015) TLR 3 ligand poly IC attenuates reactive astrogliosis and improves recovery of rats after focal cerebral ischemia. CNS Neurosci Ther 21(11):905\u2013913","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"4479_CR25","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.vaccine.2010.11.036","volume":"29","author":"DA Wick","year":"2011","unstructured":"Wick DA, Martin SD, Nelson BH, Webb JR (2011) Profound CD8\u2009+\u2009T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly (I: C). Vaccine 29(5):984\u2013993","journal-title":"Vaccine"},{"key":"4479_CR26","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/sigtrans.2017.55","volume":"2","author":"X Yang","year":"2017","unstructured":"Yang X, Cheng Y, Li C (2017) The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther 2:17055","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4479_CR27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-016-0160-y","volume":"4","author":"H Khong","year":"2016","unstructured":"Khong H, Overwijk WW (2016) Adjuvants for peptide-based cancer vaccines. J Immunother Cancer 4(1):56","journal-title":"J Immunother Cancer"},{"issue":"12","key":"4479_CR28","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.4049\/jimmunol.0804225","volume":"182","author":"JT Bates","year":"2009","unstructured":"Bates JT, Uematsu S, Akira S, Mizel SB (2009) Direct stimulation of tlr5\u2009+\/+\u2009CD11c\u2009+\u2009cells is necessary for the adjuvant activity of flagellin. J Immunol 182(12):7539\u20137547","journal-title":"J Immunol"},{"issue":"4","key":"4479_CR29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14760584.2018.1457443","volume":"17","author":"B Cui","year":"2018","unstructured":"Cui B, Liu X, Fang Y, Zhou P, Zhang Y, Wang Y (2018) Flagellin as a vaccine adjuvant. Expert Rev Vaccines 17(4):335\u2013349","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"4479_CR30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1634\/theoncologist.2008-0097","volume":"13","author":"EL Smits","year":"2008","unstructured":"Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13(8):859\u2013875","journal-title":"Oncologist"},{"issue":"6","key":"4479_CR31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jac\/48.6.751","volume":"48","author":"D Dockrell","year":"2001","unstructured":"Dockrell D, Kinghorn G (2001) Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 48(6):751\u2013755","journal-title":"J Antimicrob Chemother"},{"issue":"21","key":"4479_CR32","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2012.10.016","volume":"31","author":"O Levy","year":"2013","unstructured":"Levy O, Goriely S, Kollmann TR (2013) Immune response to vaccine adjuvants during the first year of life. Vaccine 31(21):2500\u20132505","journal-title":"Vaccine"},{"issue":"1","key":"4479_CR33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(99)00033-9","volume":"43","author":"I Arany","year":"1999","unstructured":"Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH et al (1999) Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antivir Res 43(1):55\u201363","journal-title":"Antivir Res"},{"key":"4479_CR34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-016-0160-y","volume":"4","author":"H Khong","year":"2016","unstructured":"Khong H, Overwijk WW (2016) Adjuvants for peptide-based cancer vaccines. J Immunother Cancer 4:56","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4479_CR35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cyto.2008.12.007","volume":"46","author":"C Hartoonian","year":"2009","unstructured":"Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N et al (2009) Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine 46(1):43\u201350","journal-title":"Cytokine"},{"issue":"6","key":"4479_CR36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.vaccine.2011.12.029","volume":"30","author":"J Tang","year":"2012","unstructured":"Tang J, Yin R, Tian Y, Huang Z, Shi J, Fu X et al (2012) A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57\/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice. Vaccine 30(6):1071\u20131082","journal-title":"Vaccine"},{"issue":"2","key":"4479_CR37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2249.2006.03297.x","volume":"147","author":"C Venier","year":"2007","unstructured":"Venier C, Guthmann M, Fernandez L, Fainboim L (2007) Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant. Clin Exp Immunol 147(2):379\u2013388","journal-title":"Clin Exp Immunol"},{"issue":"50","key":"4479_CR38","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1016\/j.vaccine.2005.07.049","volume":"23","author":"I Torr\u00e9ns","year":"2005","unstructured":"Torr\u00e9ns I, Mendoza O, Batte A, Reyes O, Fern\u00e1ndez LE, Mesa C et al (2005) Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 23(50):5768\u20135774","journal-title":"Vaccine"},{"issue":"33","key":"4479_CR39","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.vaccine.2009.05.032","volume":"27","author":"H-X Sun","year":"2009","unstructured":"Sun H-X, Xie Y, Ye Y-P (2009) ISCOMs and ISCOMATRIX\u2122. Vaccine 27(33):4388\u20134401","journal-title":"Vaccine"},{"issue":"2","key":"4479_CR40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1440-1711.2005.01319.x","volume":"83","author":"MT Sanders","year":"2005","unstructured":"Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) ISCOMTM-based vaccines: the second decade. Immunol Cell Biol 83(2):119\u2013128","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"4479_CR41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/vaccines4040042","volume":"4","author":"F Manfredi","year":"2016","unstructured":"Manfredi F, di Bonito P, Ridolfi B, Anticoli S, Arenaccio C, Chiozzini C et al (2016) The CD8+ T cell-mediated immunity induced by HPV-E6 uploaded in engineered exosomes is improved by ISCOMATRIXTM adjuvant. Vaccines 4(4):42","journal-title":"Vaccines"},{"issue":"1","key":"4479_CR42","doi-asserted-by":"crossref","first-page":"e116389","DOI":"10.1371\/journal.pone.0116389","volume":"10","author":"S Peng","year":"2015","unstructured":"Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD et al (2015) Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One 10(1):e116389","journal-title":"PLoS One"},{"issue":"11","key":"4479_CR43","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/ijc.23828","volume":"123","author":"M Tsuchiya","year":"2008","unstructured":"Tsuchiya M, Kono H, Matsuda M, Fujii H, Rusyn I (2008) Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int J Cancer 123(11):2503\u20132511","journal-title":"Int J Cancer"},{"issue":"4","key":"4479_CR44","first-page":"389","volume":"5","author":"J Cho","year":"1991","unstructured":"Cho J, Sato N, Kikuchi K (1991) Prophylactic anti-tumor effect of Hochu-ekki-to (TJ41) by enhancing natural killer cell activity. In vivo (Athens, Greece) 5(4):389\u2013391","journal-title":"In vivo (Athens, Greece)"},{"issue":"36","key":"4479_CR45","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1016\/j.vaccine.2012.06.027","volume":"30","author":"A Taguchi","year":"2012","unstructured":"Taguchi A, Kawana K, Yokoyama T, Adachi K, Yamashita A, Tomio K et al (2012) Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. Vaccine 30(36):5368\u20135372","journal-title":"Vaccine"},{"issue":"1\u20133","key":"4479_CR46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","volume":"47","author":"K Lin","year":"2010","unstructured":"Lin K, Roosinovich E, Ma B, Hung C-F, Wu T-C (2010) Therapeutic HPV DNA vaccines. Immunol Res 47(1\u20133):86\u2013112","journal-title":"Immunol Res"},{"issue":"1","key":"4479_CR47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-3083.2011.02620.x","volume":"75","author":"E Mohit","year":"2012","unstructured":"Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S (2012) The Contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL\/6 mouse model. Scand J Immunol 75(1):27\u201337","journal-title":"Scand J Immunol"},{"issue":"1","key":"4479_CR48","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/or.2013.2445","volume":"30","author":"J Zong","year":"2013","unstructured":"Zong J, Wang C, Liu B, Liu M, Cao Y, Sun X et al (2013) Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy. Oncol Rep 30(1):407\u2013412","journal-title":"Oncol Rep"},{"issue":"3","key":"4479_CR49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/10408444.2013.861798","volume":"44","author":"ML Weiner","year":"2014","unstructured":"Weiner ML (2014) Food additive carrageenan: part II: a critical review of carrageenan in vivo safety studies. Crit Rev Toxicol 44(3):244\u2013269","journal-title":"Crit Rev Toxicol"},{"issue":"10","key":"4479_CR50","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jnutbio.2009.07.002","volume":"21","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Liu H, Zhang Z, Jam M, Dudeja PK, Michel G et al (2010) Carrageenan-induced innate immune response is modified by enzymes that hydrolyze distinct galactosidic bonds. J Nutr Biochem 21(10):906\u2013913","journal-title":"J Nutr Biochem"},{"issue":"18","key":"4479_CR51","doi-asserted-by":"crossref","first-page":"29996","DOI":"10.18632\/oncotarget.15610","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Aipire A, Li J, Zhu H, Wang Y, Guo W et al (2017) \u03bb-Carrageenan improves the antitumor effect of dendritic cell based vaccine. Oncotarget 8(18):29996","journal-title":"Oncotarget"},{"issue":"3","key":"4479_CR52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1586\/14760584.2014.880340","volume":"13","author":"RK Sharma","year":"2014","unstructured":"Sharma RK, Yolcu ES, Shirwan H (2014) SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines 13(3):387\u2013398","journal-title":"Expert Rev Vaccines"},{"issue":"22","key":"4479_CR53","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1158\/0008-5472.CAN-14-1768-A","volume":"74","author":"AK Srivastava","year":"2014","unstructured":"Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H (2014) SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res 74(22):6441\u20136451","journal-title":"Cancer Res"},{"key":"4479_CR54","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.vaccine.2006.06.014","volume":"24","author":"LA Koutsky","year":"2006","unstructured":"Koutsky LA, Harper DM (2006) Current findings from prophylactic HPV vaccine trials. Vaccine 24:S114\u2013S121","journal-title":"Vaccine"},{"issue":"36","key":"4479_CR55","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1016\/j.vaccine.2012.06.010","volume":"30","author":"C Sharma","year":"2012","unstructured":"Sharma C, Dey B, Wahiduzzaman M, Singh N (2012) Human papillomavirus 16 L1\u2013E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. Vaccine 30(36):5417\u20135424","journal-title":"Vaccine"},{"issue":"1","key":"4479_CR56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12985-015-0364-7","volume":"12","author":"W-H Wu","year":"2015","unstructured":"Wu W-H, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA (2015) Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J 12(1):140","journal-title":"Virol J"},{"issue":"8","key":"4479_CR57","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","volume":"179","author":"MS Bijker","year":"2007","unstructured":"Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH (2007) CD8\u2009+\u2009CTL priming by exact peptide epitopes in incomplete Freund\u2019s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179(8):5033\u20135040","journal-title":"J Immunol"},{"issue":"5","key":"4479_CR58","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14737140.7.5.753","volume":"7","author":"G Badaracco","year":"2007","unstructured":"Badaracco G, Venuti A (2007) Human papillomavirus therapeutic vaccines in head and neck tumors. Expert Rev Anticancer Ther 7(5):753\u2013766","journal-title":"Expert Rev Anticancer Ther"},{"issue":"24","key":"4479_CR59","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1016\/j.vaccine.2006.03.079","volume":"24","author":"P Daftarian","year":"2006","unstructured":"Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG et al (2006) Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 24(24):5235\u20135244","journal-title":"Vaccine"},{"issue":"2","key":"4479_CR60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00705-013-1819-z","volume":"159","author":"A Monroy-Garc\u00eda","year":"2014","unstructured":"Monroy-Garc\u00eda A, G\u00f3mez-Lim MA, Weiss-Steider B, Hern\u00e1ndez-Montes J, Huerta-Yepez S, Rangel-Santiago JF et al (2014) Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Arch Virol 159(2):291\u2013305","journal-title":"Arch Virol"},{"issue":"8","key":"4479_CR61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0167-7799(01)01670-5","volume":"19","author":"EJ Ryan","year":"2001","unstructured":"Ryan EJ, Daly LM, Mills KH (2001) Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 19(8):293\u2013304","journal-title":"Trends Biotechnol"},{"issue":"1","key":"4479_CR62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1574-695X.2007.00339.x","volume":"52","author":"Y Xu","year":"2008","unstructured":"Xu Y, Zhang H, Xu X (2008) Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles. FEMS Immunol Med Microbiol 52(1):99\u2013109","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"8","key":"4479_CR63","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.vaccine.2010.11.091","volume":"29","author":"VP Da Hora","year":"2011","unstructured":"Da Hora VP, Concei\u00e7\u00e3o FR, Dellagostin OA, Doolan DL (2011) Non-toxic derivatives of LT as potent adjuvants. Vaccine 29(8):1538\u20131544","journal-title":"Vaccine"},{"issue":"1","key":"4479_CR64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.imlet.2009.10.005","volume":"128","author":"R Brunner","year":"2010","unstructured":"Brunner R, Jensen-Jarolim E, Pali-Sch\u00f6ll I (2010) The ABC of clinical and experimental adjuvants\u2014a brief overview. Immunol Lett 128(1):29\u201335","journal-title":"Immunol Lett"},{"issue":"4","key":"4479_CR65","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/mi.2014.105","volume":"8","author":"J Jee","year":"2015","unstructured":"Jee J, Bonnegarde-Bernard A, Duverger A, Iwakura Y, Cormet-Boyaka E, Martin TL et al (2015) Neutrophils negatively regulate induction of mucosal IgA responses after sublingual immunization. Mucosal Immunol 8(4):735","journal-title":"Mucosal Immunol"},{"issue":"17","key":"4479_CR66","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1016\/j.vaccine.2007.01.010","volume":"25","author":"PR Manuri","year":"2007","unstructured":"Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell S, Courtney AN et al (2007) Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 25(17):3302\u20133310","journal-title":"Vaccine"},{"issue":"1","key":"4479_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0133-y","volume":"7","author":"J Xu","year":"2018","unstructured":"Xu J, Li S, Wang X, Liu J, Shan P, Zhou Y et al (2018) Systemic and mucosal humoral immune responses induced by the JY-adjuvanted nasal spray H7N9 vaccine in mice. Emerg Microbes Infect 7(1):1\u20139","journal-title":"Emerg Microbes Infect"},{"key":"4479_CR68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.imlet.2016.09.011","volume":"179","author":"Y Hua","year":"2016","unstructured":"Hua Y, Jiao Y-Y, Ma Y, Peng X-L, Fu Y-H, Zheng Y-P et al (2016) DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice. Immunol Lett 179:95\u2013101","journal-title":"Immunol Lett"},{"issue":"36","key":"4479_CR69","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1016\/j.vaccine.2012.06.035","volume":"30","author":"M Tafaghodi","year":"2012","unstructured":"Tafaghodi M, Saluja V, Kersten GF, Kraan H, Sl\u00fctter B, Amorij J-P et al (2012) Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics. Vaccine 30(36):5341\u20135348","journal-title":"Vaccine"},{"issue":"4","key":"4479_CR70","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10529-014-1739-3","volume":"37","author":"F Ma","year":"2015","unstructured":"Ma F, Zhang Q, Zheng L (2015) Interleukin\/chitosan (JY) adjuvant enhances the mucosal immunity of human papillomavirus 16 L1 virus-like particles in mice. Biotechnol Lett 37(4):773\u2013777","journal-title":"Biotechnol Lett"},{"issue":"2","key":"4479_CR71","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ijc.29402","volume":"137","author":"R Heidenreich","year":"2015","unstructured":"Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P et al (2015) A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 137(2):372\u2013384","journal-title":"Int J Cancer"},{"issue":"5","key":"4479_CR72","doi-asserted-by":"crossref","first-page":"FSO300","DOI":"10.4155\/fsoa-2017-0151","volume":"4","author":"K Lundstrom","year":"2018","unstructured":"Lundstrom K (2018) Latest development on RNA-based drugs and vaccines. Future Sci OA 4(5):FSO300","journal-title":"Future Sci OA"},{"issue":"8","key":"4479_CR73","doi-asserted-by":"crossref","first-page":"e43031","DOI":"10.1371\/journal.pone.0043031","volume":"7","author":"K Onomoto","year":"2012","unstructured":"Onomoto K, Jogi M, Yoo JS, Narita R, Morimoto S, Takemura A et al (2012) Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. PLoS One 7(8):e43031","journal-title":"PLoS One"},{"issue":"1","key":"4479_CR74","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00262-016-1923-5","volume":"66","author":"L Circelli","year":"2017","unstructured":"Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello ML, Buonaguro FM et al (2017) Immunological effects of a novel RNA-based adjuvant in liver cancer patients. Cancer Immunol Immunother 66(1):103\u2013112","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"4479_CR75","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1586\/erv.10.111","volume":"9","author":"HE Sahly","year":"2010","unstructured":"Sahly HE (2010) MF59\u2122 as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 9(10):1135\u20131141","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"4479_CR76","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-3083.1995.tb03696.x","volume":"42","author":"X Zhu","year":"1995","unstructured":"Zhu X, Tommasino M, Vousden K, Sadovnikava E, Rappuoli R, Crawford L et al (1995) Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. Scand J Immunol 42(5):557\u2013563","journal-title":"Scand J Immunol"},{"issue":"19","key":"4479_CR77","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1016\/j.vaccine.2007.01.111","volume":"25","author":"J Aguilar","year":"2007","unstructured":"Aguilar J, Rodriguez E (2007) Vaccine adjuvants revisited. Vaccine 25(19):3752\u20133762","journal-title":"Vaccine"},{"issue":"2","key":"4479_CR78","doi-asserted-by":"crossref","first-page":"e1081328","DOI":"10.1080\/2162402X.2015.1081328","volume":"5","author":"SE Lee","year":"2016","unstructured":"Lee SE, Hong SH, Verma V, Lee YS, Duong T-MN, Jeong K et al (2016) Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. Oncoimmunology 5(2):e1081328","journal-title":"Oncoimmunology"},{"issue":"4","key":"4479_CR79","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.immuni.2011.03.019","volume":"34","author":"E Kuroda","year":"2011","unstructured":"Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S et al (2011) Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 34(4):514\u2013526","journal-title":"Immunity"},{"issue":"7","key":"4479_CR80","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ni1082","volume":"5","author":"AL Ackerman","year":"2004","unstructured":"Ackerman AL, Cresswell P (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5(7):678","journal-title":"Nat Immunol"},{"issue":"3","key":"4479_CR81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1939-1676.2003.tb02448.x","volume":"17","author":"AR Spickler","year":"2003","unstructured":"Spickler AR, Roth JA (2003) Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 17(3):273\u2013281","journal-title":"J Vet Intern Med"},{"issue":"13","key":"4479_CR82","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1128\/JVI.76.13.6480-6486.2002","volume":"76","author":"A-L Combita","year":"2002","unstructured":"Combita A-L, Touz\u00e9 A, Bousarghin L, Christensen ND, Coursaget P (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76(13):6480\u20136486","journal-title":"J Virol"},{"issue":"6","key":"4479_CR83","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1128\/JVI.73.6.4882-4889.1999","volume":"73","author":"WI White","year":"1999","unstructured":"White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim S-J, Hewitt LA et al (1999) Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73(6):4882\u20134889","journal-title":"J Virol"},{"key":"4479_CR84","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1743-422X-9-199","volume":"9","author":"A Fukui","year":"2012","unstructured":"Fukui A, Matsueda S, Kawano K, Tsuda N, Komatsu N, Shichijo S et al (2012) Identification of B cell epitopes reactive to human papillomavirus type-16L1-derived peptides. Virol J 9:199","journal-title":"Virol J"},{"key":"4479_CR85","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12985-015-0364-7","volume":"12","author":"WH Wu","year":"2015","unstructured":"Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA (2015) Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J 12:140","journal-title":"Virol J"},{"issue":"6","key":"4479_CR86","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.vaccine.2009.11.048","volume":"28","author":"T Senger","year":"2010","unstructured":"Senger T, Sch\u00e4dlich L, Textor S, Klein C, Michael KM, Buck CB et al (2010) Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs. Vaccine 28(6):1583\u20131593","journal-title":"Vaccine"},{"issue":"13","key":"4479_CR87","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0264-410X(02)00679-5","volume":"21","author":"TW Tobery","year":"2003","unstructured":"Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L et al (2003) Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 21(13):1539\u20131547","journal-title":"Vaccine"},{"issue":"10","key":"4479_CR88","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/1940-6207.CAPR-15-0164","volume":"8","author":"H Seitz","year":"2015","unstructured":"Seitz H, Ribeiro-M\u00fcller L, Canali E, Bolchi A, Tommasino M, Ottonello S et al (2015) Robust in vitro and in vivo neutralization against multiple high-risk HPV types induced by a thermostable thioredoxin-L2 vaccine. Cancer Prev Res 8(10):932\u2013941","journal-title":"Cancer Prev Res"},{"key":"4479_CR89","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejpb.2015.05.009","volume":"94","author":"KJ Hassett","year":"2015","unstructured":"Hassett KJ, Meinerz NM, Semmelmann F, Cousins MC, Garcea RL, Randolph TW (2015) Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Eur J Pharm Biopharm 94:220\u2013228","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"4479_CR90","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/viro.1998.9372","volume":"250","author":"ML De Bruijn","year":"1998","unstructured":"De Bruijn ML, Greenstone HL, Vermeulen H, Melief CJ, Lowy DR, Schiller JT et al (1998) L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250(2):371\u2013376","journal-title":"Virology"},{"key":"4479_CR91","doi-asserted-by":"crossref","first-page":"34686","DOI":"10.1038\/srep34686","volume":"6","author":"W-X Xu","year":"2016","unstructured":"Xu W-X, Wang J, Tang H-P, He Y-P, Zhu Q-X, Gupta SK et al (2016) Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58. Sci Rep 6:34686","journal-title":"Sci Rep"},{"issue":"11","key":"4479_CR92","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.vaccine.2006.11.049","volume":"25","author":"K Slupetzky","year":"2007","unstructured":"Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND et al (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25(11):2001\u20132010","journal-title":"Vaccine"},{"issue":"1","key":"4479_CR93","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0042-6822(95)80032-8","volume":"206","author":"ME Hagensee","year":"1995","unstructured":"Hagensee ME, Carter JJ, Wipf GC, Galloway DA (1995) Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 206(1):174\u2013182","journal-title":"Virology"},{"issue":"2","key":"4479_CR94","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ygyno.2004.10.028","volume":"96","author":"Y Qin","year":"2005","unstructured":"Qin Y, Wang X, Cui H, Cheung Y, Hu M, Zhu S et al (2005) Human papillomavirus type 16 E7 peptide38\u201361 linked with an immunoglobulin G fragment provides protective immunity in mice. Gynecol Oncol 96(2):475\u2013483","journal-title":"Gynecol Oncol"},{"issue":"31","key":"4479_CR95","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1016\/j.vaccine.2014.05.050","volume":"32","author":"KS Korsholm","year":"2014","unstructured":"Korsholm KS, Hansen J, Karlsen K, Filskov J, Mikkelsen M, Lindenstr\u00f8m T et al (2014) Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. Vaccine 32(31):3927\u20133935","journal-title":"Vaccine"},{"issue":"9\u201310","key":"4479_CR96","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0264-410X(00)00312-1","volume":"19","author":"CE Greer","year":"2000","unstructured":"Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL et al (2000) The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine 19(9\u201310):1008\u20131012","journal-title":"Vaccine"},{"issue":"3","key":"4479_CR97","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/21645515.2017.1420446","volume":"7","author":"C Liu","year":"2018","unstructured":"Liu C, Chu X, Sun P, Feng X, Huang W, Liu H, Ma Y (2018) Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model. Hum Vaccines Immunother 7(3):931\u2013940","journal-title":"Hum Vaccines Immunother"},{"key":"4479_CR98","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/135965350400900419","volume":"9","author":"E-J Freyschmidt","year":"2004","unstructured":"Freyschmidt E-J, Alonso A, Hartmann G, Gissmann L (2004) Activation of dendritic cells and induction of T cell responses by HPV 16 L1\/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 9:479\u2013490","journal-title":"Antivir Ther"},{"issue":"8","key":"4479_CR99","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/sj.mt.6300149","volume":"15","author":"GW Ye","year":"2007","unstructured":"Ye GW, Park J-B, Park Y-J, Choi YS, Sin J-I (2007) Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther 15(8):1564\u20131570","journal-title":"Mol Ther"},{"issue":"3","key":"4479_CR100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.vaccine.2004.06.008","volume":"23","author":"MJ Welters","year":"2004","unstructured":"Welters MJ, Filippov DV, van den Eeden SJ, Franken KL, Nouta J, Valentijn ARP et al (2004) Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine 23(3):305\u2013311","journal-title":"Vaccine"},{"issue":"1","key":"4479_CR101","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2567.2004.01851.x","volume":"112","author":"TG Kim","year":"2004","unstructured":"Kim TG, Kim CH, Won EH, Bae SM, Ahn WS, Park JB et al (2004) CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology 112(1):117\u2013125","journal-title":"Immunology"},{"issue":"7","key":"4479_CR102","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/ijc.21546","volume":"118","author":"M Reini\u0161","year":"2006","unstructured":"Reini\u0161 M, \u0160\u00edmov\u00e1 J, Buben\u00edk J (2006) Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and-proficient HPV16-associated tumours. Int J Cancer 118(7):1836\u20131842","journal-title":"Int J Cancer"},{"key":"4479_CR103","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jconrel.2013.10.027","volume":"173","author":"Y-C Song","year":"2014","unstructured":"Song Y-C, Cheng H-Y, Leng C-H, Chiang S-K, Lin C-W, Chong P et al (2014) A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity. J Control Release 173:158\u2013165","journal-title":"J Control Release"},{"issue":"12","key":"4479_CR104","doi-asserted-by":"crossref","first-page":"e115711","DOI":"10.1371\/journal.pone.0115711","volume":"9","author":"L Song","year":"2014","unstructured":"Song L, Yang M-C, Knoff J, Wu T-C, Hung C-F (2014) Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment. PLoS One 9(12):e115711","journal-title":"PLoS One"},{"issue":"2","key":"4479_CR105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.molimm.2014.12.007","volume":"64","author":"S Liao","year":"2015","unstructured":"Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H et al (2015) A novel \u201cpriming-boosting\u201d strategy for immune interventions in cervical cancer. Mol Immunol 64(2):295\u2013305","journal-title":"Mol Immunol"},{"issue":"2","key":"4479_CR106","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/mi.2012.83","volume":"6","author":"S Domingos-Pereira","year":"2013","unstructured":"Domingos-Pereira S, Decrausaz L, Derr\u00e9 L, Bobst M, Romero P, Schiller JT et al (2013) Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 6(2):393","journal-title":"Mucosal Immunol"},{"key":"4479_CR107","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fimmu.2017.00226","volume":"8","author":"AC Gomes","year":"2017","unstructured":"Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi AE et al (2017) Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines. Front Immunol 8:226","journal-title":"Front Immunol"},{"issue":"5","key":"4479_CR108","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.vaccine.2010.11.063","volume":"29","author":"TH Kang","year":"2011","unstructured":"Kang TH, Monie A, Wu LS-F, Pang X, Hung C-F, Wu T-C (2011) Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine 29(5):1082\u20131089","journal-title":"Vaccine"},{"issue":"27","key":"4479_CR109","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.vaccine.2009.03.073","volume":"27","author":"D Pokorn\u00e1","year":"2009","unstructured":"Pokorn\u00e1 D, Pol\u00e1kov\u00e1 I, Kindlov\u00e1 M, Du\u0161kov\u00e1 M, Ludv\u00edkov\u00e1 V, Gabriel P et al (2009) Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. Vaccine 27(27):3519\u20133529","journal-title":"Vaccine"},{"issue":"2","key":"4479_CR110","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.21360","volume":"118","author":"K Dell","year":"2006","unstructured":"Dell K, Koesters R, Gissmann L (2006) Transcutaneous immunization in mice: Induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors. Int J Cancer 118(2):364\u2013372","journal-title":"Int J Cancer"},{"issue":"32","key":"4479_CR111","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1016\/j.vaccine.2007.05.041","volume":"25","author":"AG Chandy","year":"2007","unstructured":"Chandy AG, Nurkkala M, Josefsson A, Eriksson K (2007) Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours. Vaccine 25(32):6037\u20136046","journal-title":"Vaccine"},{"issue":"12","key":"4479_CR112","doi-asserted-by":"crossref","first-page":"602","DOI":"10.17221\/4438-VETMED","volume":"56","author":"X Mao","year":"2011","unstructured":"Mao X, Chen X, Zhang W, Wang J, Liu L, Zhou Q et al (2011) TLR agonists activate HPV11 E7-pulsed DCs to promote a specific T cell response in a murine model. Veterinarni Medicina 56(12):602\u2013611","journal-title":"Veterinarni Medicina"},{"issue":"2","key":"4479_CR113","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7774\/cevr.2013.2.2.128","volume":"2","author":"CT Nguyen","year":"2013","unstructured":"Nguyen CT, Hong SH, Ung TT, Verma V, Kim SY, Rhee JH et al (2013) Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model. Clin Exp Vaccine Res 2(2):128\u2013134","journal-title":"Clin Exp Vaccine Res"},{"issue":"2","key":"4479_CR114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4161\/cbt.9.2.10391","volume":"9","author":"F Ren","year":"2010","unstructured":"Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X et al (2010) Heat shock protein 110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E7 in mice. Cancer Biol Ther 9(2):134\u2013141","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"4479_CR115","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/JVI.74.6.2888-2894.2000","volume":"74","author":"D-W Liu","year":"2000","unstructured":"Liu D-W, Tsao Y-P, Kung JT, Ding Y-A, Sytwu H-K, Xiao X et al (2000) Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74(6):2888\u20132894","journal-title":"J Virol"},{"issue":"10","key":"4479_CR116","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.vaccine.2007.12.034","volume":"26","author":"B Liu","year":"2008","unstructured":"Liu B, Ye D, Song X, Zhao X, Yi L, Song J et al (2008) A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 26(10):1387\u20131396","journal-title":"Vaccine"},{"issue":"1","key":"4479_CR117","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1574-695X.2007.00339.x","volume":"52","author":"Y Xu","year":"2007","unstructured":"Xu Y, Zhang H, Xu X (2007) Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles. FEMS Immunol Med Microbiol 52(1):99\u2013109","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"10","key":"4479_CR118","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1128\/JVI.72.10.8220-8229.1998","volume":"72","author":"C Balmelli","year":"1998","unstructured":"Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D (1998) Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72(10):8220\u20138229","journal-title":"J Virol"},{"issue":"12","key":"4479_CR119","doi-asserted-by":"crossref","first-page":"7851","DOI":"10.4049\/jimmunol.0803740","volume":"183","author":"N \u00c7uburu","year":"2009","unstructured":"\u00c7uburu N, Kweon M-N, Hervouet C, Cha H-R, Pang Y-YS, Holmgren J et al (2009) Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 183(12):7851\u20137859","journal-title":"J Immunol"},{"issue":"29\u201330","key":"4479_CR120","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1016\/j.vaccine.2004.03.054","volume":"22","author":"J Malliaros","year":"2004","unstructured":"Malliaros J, Quinn C, Arnold FH, Pearse MJ, Drane DP, Stewart TJ et al (2004) Association of antigens to ISCOMATRIX\u2122 adjuvant using metal chelation leads to improved CTL responses. Vaccine 22(29\u201330):3968\u20133975","journal-title":"Vaccine"},{"issue":"3","key":"4479_CR121","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0264-410X(95)00179-5","volume":"14","author":"I Tarpey","year":"1996","unstructured":"Tarpey I, Stacey SN, McIndoe A, Davies DH (1996) Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). Vaccine 14(3):230\u2013236","journal-title":"Vaccine"},{"issue":"13","key":"4479_CR122","first-page":"3654","volume":"62","author":"R Franconi","year":"2002","unstructured":"Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A et al (2002) Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 62(13):3654\u20133658","journal-title":"Cancer Res"},{"issue":"16","key":"4479_CR123","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.vaccine.2007.01.018","volume":"25","author":"S Massa","year":"2007","unstructured":"Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V et al (2007) Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25(16):3018\u20133021","journal-title":"Vaccine"},{"issue":"7","key":"4479_CR124","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.vaccine.2008.11.099","volume":"27","author":"B Karanam","year":"2009","unstructured":"Karanam B, Gambhira R, Peng S, Jagu S, Kim D-J, Ketner GW et al (2009) Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 27(7):1040\u20131049","journal-title":"Vaccine"},{"issue":"3","key":"4479_CR125","doi-asserted-by":"crossref","first-page":"e0174038","DOI":"10.1371\/journal.pone.0174038","volume":"12","author":"M Esquerr\u00e9","year":"2017","unstructured":"Esquerr\u00e9 M, Bouillette-Marussig M, Goubier A, Momot M, Gonindard C, Keller H et al (2017) GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression. PLoS One 12(3):e0174038","journal-title":"PLoS One"},{"issue":"36","key":"4479_CR126","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1016\/j.vaccine.2010.06.073","volume":"28","author":"RK Sharma","year":"2010","unstructured":"Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky R-H, Madireddi S et al (2010) SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine 28(36):5794\u20135802","journal-title":"Vaccine"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-019-04479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-019-04479-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-019-04479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T17:28:07Z","timestamp":1665163687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-019-04479-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4479"],"URL":"https:\/\/doi.org\/10.1007\/s00705-019-04479-4","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}